DPV-001
Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) and other solid tumors
Key Facts
About UbiVac
UbiVac is a private, clinical-stage biotech focused on disrupting cancer treatment with its 'Dark Matter' immunotherapy platform, which targets non-mutated, shared neoantigens derived from the 'Dark Genome.' The company's lead program, DPV-001, has demonstrated compelling clinical results, including a median overall survival of 25.5 months in PD-1-naïve patients, doubling the standard-of-care benchmark. With in-house GMP manufacturing and a discovery engine aimed at identifying novel targets for multiple therapeutic modalities, UbiVac is positioned to advance a potential universal cancer vaccine while mining its platform for new drug discovery opportunities. The company is led by renowned immunotherapy expert Dr. Bernard A. Fox and is closely aligned with the Earle A. Chiles Research Institute.
View full company profile